SG11201702309RA - Methods and compositions for generating or maintaining pluripotent cells - Google Patents

Methods and compositions for generating or maintaining pluripotent cells

Info

Publication number
SG11201702309RA
SG11201702309RA SG11201702309RA SG11201702309RA SG11201702309RA SG 11201702309R A SG11201702309R A SG 11201702309RA SG 11201702309R A SG11201702309R A SG 11201702309RA SG 11201702309R A SG11201702309R A SG 11201702309RA SG 11201702309R A SG11201702309R A SG 11201702309RA
Authority
SG
Singapore
Prior art keywords
compositions
generating
methods
pluripotent cells
maintaining pluripotent
Prior art date
Application number
SG11201702309RA
Other languages
English (en)
Inventor
Junko Kuno
Wojtek Auerbach
David M Valenzuela
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201702309RA publication Critical patent/SG11201702309RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
SG11201702309RA 2014-10-15 2015-10-15 Methods and compositions for generating or maintaining pluripotent cells SG11201702309RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462064384P 2014-10-15 2014-10-15
PCT/US2015/055776 WO2016061374A1 (en) 2014-10-15 2015-10-15 Methods and compositions for generating or maintaining pluripotent cells

Publications (1)

Publication Number Publication Date
SG11201702309RA true SG11201702309RA (en) 2017-04-27

Family

ID=54361190

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913797YA SG10201913797YA (en) 2014-10-15 2015-10-15 Methods and compositions for generating or maintaining pluripotent cells
SG11201702309RA SG11201702309RA (en) 2014-10-15 2015-10-15 Methods and compositions for generating or maintaining pluripotent cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201913797YA SG10201913797YA (en) 2014-10-15 2015-10-15 Methods and compositions for generating or maintaining pluripotent cells

Country Status (18)

Country Link
US (2) US10428310B2 (es)
EP (2) EP3207124B1 (es)
JP (1) JP2017536811A (es)
KR (1) KR20170070136A (es)
CN (1) CN107002042A (es)
AU (1) AU2015332451A1 (es)
BR (1) BR112017007770A2 (es)
CA (1) CA2963315A1 (es)
CY (1) CY1122179T1 (es)
DK (1) DK3207124T3 (es)
ES (1) ES2741387T3 (es)
IL (1) IL251576A0 (es)
MX (1) MX2017004890A (es)
PL (1) PL3207124T3 (es)
PT (1) PT3207124T (es)
RU (1) RU2706965C2 (es)
SG (2) SG10201913797YA (es)
WO (1) WO2016061374A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9149026B2 (en) 2010-06-11 2015-10-06 Regeneron Pharmaceuticals, Inc. Production of fertile XY animals from XY ES cells
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
EP2746386A1 (en) * 2012-12-21 2014-06-25 Lonza Cologne GmbH Materials and methods for cell culture
BR112015026197B1 (pt) 2013-04-16 2022-12-06 Regeneron Pharmaceuticals, Inc Método para modificação marcada de um lócus genômico de interesse em uma célula de rato pluripotente
WO2015006725A2 (en) 2013-07-12 2015-01-15 Cedars-Sinai Medical Center Generation of induced pluripotent stem cells from normal human mammary epithelial cells
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
RU2685914C1 (ru) 2013-12-11 2019-04-23 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
ES2784754T3 (es) 2014-06-06 2020-09-30 Regeneron Pharma Métodos y composiciones para modificar un locus objetivo
DK3161128T3 (en) 2014-06-26 2018-11-05 Regeneron Pharma METHODS AND COMPOSITIONS FOR TARGETED GENTICAL MODIFICATIONS AND PROCEDURES FOR USE THEREOF
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
ES2741387T3 (es) 2014-10-15 2020-02-10 Regeneron Pharma Métodos y composiciones para generar o mantener células pluripotentes
LT3221457T (lt) 2014-11-21 2019-06-10 Regeneron Pharmaceuticals, Inc. Nukreipiančios genetinės modifikacijos būdai ir kompozicijos, naudojant suporuotas kreipiančiąsias rnr sekas
US10787644B2 (en) * 2014-12-15 2020-09-29 Rxcell Inc. Methods and compositions for rapid generation of single and multiplexed reporters in cells
NZ732895A (en) 2014-12-19 2022-05-27 Regeneron Pharma Methods and compositions for targeted genetic modification through single-step multiple targeting
RU2729407C1 (ru) 2015-09-17 2020-08-06 Регенерон Фармасьютикалз, Инк. Селекция плюрипотентных клеток для продуцирования фертильных xy самок мышей
EP3365357B1 (en) 2015-10-23 2024-02-14 President and Fellows of Harvard College Evolved cas9 proteins for gene editing
CA3022319A1 (en) * 2016-05-06 2017-11-09 Tod M. Woolf Improved methods for genome editing with and without programmable nucleases
US10221395B2 (en) 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
US11572545B2 (en) 2016-06-16 2023-02-07 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
AU2017306676B2 (en) 2016-08-03 2024-02-22 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018057782A1 (en) * 2016-09-23 2018-03-29 University Of Utah Research Foundation Methods of preventing stem cell differentiation using a pask inhibitor
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
JP2018082639A (ja) * 2016-11-21 2018-05-31 学校法人千葉工業大学 体細胞から人工多能性幹細胞を製造する方法及び人工多能性幹細胞を未分化のまま培養するための培地
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
CN108552156A (zh) * 2017-11-13 2018-09-21 广东艾时代生物科技有限责任公司 一种无血清的诱导多功能干细胞冻存液及冻存方法
JP2022526908A (ja) 2019-03-19 2022-05-27 ザ ブロード インスティテュート，インコーポレーテッド 編集ヌクレオチド配列を編集するための方法および組成物
KR20220129584A (ko) * 2020-01-14 2022-09-23 아지노모토 가부시키가이샤 삼투압 저감 배지
AU2021267940A1 (en) 2020-05-08 2022-12-08 President And Fellows Of Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7026462B2 (en) 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7947469B2 (en) 2001-01-22 2011-05-24 Gendaq, Ltd. Modulation of HIV infection
EP1353941B1 (en) 2001-01-22 2013-03-13 Sangamo BioSciences, Inc. Modified zinc finger binding proteins
CA2474486C (en) 2002-01-23 2013-05-14 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
CA2477112A1 (en) 2002-02-27 2003-09-04 Yasumitsu Nagao A method for producing germline chimeric animal
JP2005520519A (ja) 2002-03-15 2005-07-14 セレクティス ハイブリッドおよび単鎖メガヌクレアーゼならびにその使用
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
EP2806025B1 (en) 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
WO2004031346A2 (en) 2002-09-06 2004-04-15 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US20030175968A1 (en) 2002-10-30 2003-09-18 Golic Kent G. Gene targeting method
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
EP1516924A1 (en) 2003-09-17 2005-03-23 Fundacion IVI para el Estudio de la reproduccion Humana (FIVIER) Generation of human embryonic stem cells from triploid zygotes
EP1734112B1 (en) 2004-03-23 2017-08-23 Toshihiro Akaike Method of proliferating pluripotent stem cell
EP1591521A1 (en) 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
CA2579677A1 (en) 2004-09-16 2006-03-30 Sangamo Biosciences, Inc. Compositions and methods for protein production
WO2006044962A1 (en) 2004-10-19 2006-04-27 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
FR2879622B1 (fr) 2004-12-17 2008-02-01 Agronomique Inst Nat Rech Procede in vitro de production d'ovocytes ou d'oeufs presentant une modification genomique ciblee
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
US20110158974A1 (en) 2005-03-15 2011-06-30 Cellectis Heterodimeric Meganucleases and Use Thereof
EP1999249B8 (en) * 2006-03-30 2012-02-15 The University Court Of The University of Edinburgh Culture medium containing kinase inhibitors. and uses thereof
JP5514539B2 (ja) 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
GB0623635D0 (en) 2006-11-27 2007-01-03 Stem Cell Sciences Uk Ltd Pluripotent cell growth media
SI2415872T1 (sl) 2006-12-14 2016-09-30 Dow Agrosciences Llc Optimizirani nekanonični proteini s cinkovim prstom
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
CN101679977B (zh) 2007-04-26 2013-05-01 桑格摩生物科学股份有限公司 向ppp1r12c基因座的靶向整合
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
CA2755192C (en) 2009-03-20 2018-09-11 Sangamo Biosciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
US20120178647A1 (en) 2009-08-03 2012-07-12 The General Hospital Corporation Engineering of zinc finger arrays by context-dependent assembly
AU2010306377B2 (en) * 2009-10-13 2015-01-22 Stemcell Technologies Canada Inc. Manipulation of osmolality for differentiating stem cells
CA2779858C (en) 2009-10-29 2019-10-29 Aris N. Economides Multifunctional alleles
SG181601A1 (en) 2009-12-10 2012-07-30 Univ Minnesota Tal effector-mediated dna modification
WO2011078665A1 (en) 2009-12-21 2011-06-30 Keygene N.V. Improved techniques for transfecting protoplasts
US9149026B2 (en) 2010-06-11 2015-10-06 Regeneron Pharmaceuticals, Inc. Production of fertile XY animals from XY ES cells
WO2012129198A1 (en) 2011-03-23 2012-09-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for obesity and diabetes
CN102851314A (zh) * 2011-07-01 2013-01-02 中国科学院上海药物研究所 诱导性多能干细胞的制备方法和用于制备诱导性多能干细胞的培养基
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
SG10201702445TA (en) 2012-04-25 2017-04-27 Regeneron Pharma Nuclease-mediated targeting with large targeting vectors
RU2650819C2 (ru) 2012-05-07 2018-04-17 Сангамо Терапьютикс, Инк. Способы и композиции для опосредованной нуклеазой направленной интеграции трансгенов
LT3401400T (lt) 2012-05-25 2019-06-10 The Regents Of The University Of California Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui
DE202013012597U1 (de) 2012-10-23 2017-11-21 Toolgen, Inc. Zusammensetzung zum Spalten einer Ziel-DNA, umfassend eine für die Ziel-DNA spezifische guide-RNA und eine Cas-Protein-codierende Nukleinsäure oder ein Cas-Protein, sowie deren Verwendung
EP3138911B1 (en) 2012-12-06 2018-12-05 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
ES2658401T3 (es) 2012-12-12 2018-03-09 The Broad Institute, Inc. Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CA3081054A1 (en) 2012-12-17 2014-06-26 President And Fellows Of Harvard College Rna-guided human genome engineering
WO2014131833A1 (en) 2013-02-27 2014-09-04 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Gene editing in the oocyte by cas9 nucleases
BR112015026197B1 (pt) 2013-04-16 2022-12-06 Regeneron Pharmaceuticals, Inc Método para modificação marcada de um lócus genômico de interesse em uma célula de rato pluripotente
CN105531365A (zh) 2013-04-23 2016-04-27 耶达研究及发展有限公司 分离的幼稚多能干细胞和产生所述细胞的方法
ES2883131T3 (es) 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
KR20160030187A (ko) 2013-06-17 2016-03-16 더 브로드 인스티튜트, 인코퍼레이티드 간의 표적화 및 치료를 위한 ＣＲＩＳＰＲ­Ｃａｓ 시스템, 벡터 및 조성물의 전달 및 용도
WO2014204725A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
EP3011034B1 (en) 2013-06-17 2019-08-07 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
ES2777217T3 (es) 2013-06-17 2020-08-04 Broad Inst Inc Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias
DK3011032T3 (da) 2013-06-17 2020-01-20 Broad Inst Inc Fremføring, modificering og optimering af systemer, fremgangsmåder og sammensætninger til målretning mod og modellering af sygdomme og forstyrrelser i postmitotiske celler
US11306328B2 (en) 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
EA037850B1 (ru) 2013-08-29 2021-05-27 Тэмпл Юниверсити Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн Способы и композиции для рнк-направленного лечения вич-инфекции
JP5900942B2 (ja) 2013-11-06 2016-04-06 国立大学法人広島大学 核酸挿入用ベクター
LT3066201T (lt) 2013-11-07 2018-08-10 Editas Medicine, Inc. Su crispr susiję būdai ir kompozicijos su valdančiomis grnr
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
RU2685914C1 (ru) 2013-12-11 2019-04-23 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
JP6606088B2 (ja) 2014-02-24 2019-11-13 サンガモ セラピューティクス， インコーポレイテッド ヌクレアーゼ媒介性標的化組み込みのための方法および組成物
WO2015163733A1 (en) 2014-04-24 2015-10-29 Institute For Basic Science A method of selecting a nuclease target sequence for gene knockout based on microhomology
ES2784754T3 (es) 2014-06-06 2020-09-30 Regeneron Pharma Métodos y composiciones para modificar un locus objetivo
DK3161128T3 (en) 2014-06-26 2018-11-05 Regeneron Pharma METHODS AND COMPOSITIONS FOR TARGETED GENTICAL MODIFICATIONS AND PROCEDURES FOR USE THEREOF
WO2016011210A2 (en) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US20180250424A1 (en) 2014-10-10 2018-09-06 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
ES2741387T3 (es) 2014-10-15 2020-02-10 Regeneron Pharma Métodos y composiciones para generar o mantener células pluripotentes
US20170306306A1 (en) 2014-10-24 2017-10-26 Life Technologies Corporation Compositions and Methods for Enhancing Homologous Recombination
CA2963820A1 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
LT3221457T (lt) 2014-11-21 2019-06-10 Regeneron Pharmaceuticals, Inc. Nukreipiančios genetinės modifikacijos būdai ir kompozicijos, naudojant suporuotas kreipiančiąsias rnr sekas
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
NZ732895A (en) 2014-12-19 2022-05-27 Regeneron Pharma Methods and compositions for targeted genetic modification through single-step multiple targeting
EP3242938B1 (en) 2015-01-09 2020-01-08 Bio-Rad Laboratories, Inc. Detection of genome editing
GB201504223D0 (en) 2015-03-12 2015-04-29 Genome Res Ltd Biallelic genetic modification
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems

Also Published As

Publication number Publication date
EP3207124B1 (en) 2019-06-26
IL251576A0 (en) 2017-06-29
JP2017536811A (ja) 2017-12-14
US20190382730A1 (en) 2019-12-19
EP3207124A1 (en) 2017-08-23
RU2706965C2 (ru) 2019-11-21
CA2963315A1 (en) 2016-04-21
CY1122179T1 (el) 2020-11-25
AU2015332451A1 (en) 2017-04-20
RU2017116678A3 (es) 2019-05-22
DK3207124T3 (da) 2019-08-12
CN107002042A (zh) 2017-08-01
MX2017004890A (es) 2018-02-12
ES2741387T3 (es) 2020-02-10
SG10201913797YA (en) 2020-03-30
WO2016061374A1 (en) 2016-04-21
RU2017116678A (ru) 2018-11-22
US10428310B2 (en) 2019-10-01
US20160108369A1 (en) 2016-04-21
KR20170070136A (ko) 2017-06-21
BR112017007770A2 (pt) 2018-01-16
PL3207124T3 (pl) 2019-11-29
EP3561052A1 (en) 2019-10-30
PT3207124T (pt) 2019-08-27

Similar Documents

Publication Publication Date Title
IL251576A0 (en) Methods and compositions for creating or maintaining multifunctional cells
HK1243333A1 (zh) 用於修飾的t細胞的方法和組合物
HK1244826A1 (zh) 用於過繼細胞治療的方法和組合物
HK1244841A1 (zh) 用於選擇性消除所關注細胞的方法和組合物
HK1245080A1 (zh) 自然殺傷細胞的方法和組合物
HRP20192145T1 (hr) Pripravci nosača-antitijela i metode pripreme i uporabe istih
GB2535253B (en) Compositions and methods
IL271659A (en) Compositions and methods for modulating expression of complement factor B
GB201709599D0 (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
IL246879A0 (en) Preparations of Epilimod and methods of using them
GB201417828D0 (en) New methods and compositions
EP3383182C0 (en) METHODS FOR PRODUCING FUNCTIONAL HEMATOPOIETIC STEM CELLS
PL3586821T3 (pl) Kompozycje stymulujące komórki macierzyste i sposoby
SG11201702475VA (en) Methods and compositions for modulating th-gm cell function
PT3113774T (pt) Composições de grapiprant e métodos de utilização das mesmas
GB201401373D0 (en) Compositions for cells lysis and uses thereof
GB201402915D0 (en) Compositions and methods
GB201403212D0 (en) Compositions and methods